Resources

Resources from us to you. Right at your fingertips.

Phosphorex Appoints John Rigg to Board of Directors

Press Announcing John Rigg as additional Board of Directors...

Read more

Technical Bulletin| Effect of Formulation Buffer Type on LNP Size

Read more

Phosphorex and NOF CORPORATION Collaborate to Supply Lipid Nanoparticle Formulations using NOF's Proprietary Ionizable Lipid, COATSOMEĀ® SS Series

Press Announcement of Phosphorex's and NOF Corporation Collaboration....

Read more

Technical Bulletin | Side-by-Side Evaluation of Three Leading Mixing Technologies for the Fabrication and Scale-Up of LNP-based Therapeutics

Read more

Video | Running an Automated RiboGreen Assay on the Eppendorf epMotion Automated Liquid Handler

Read more

Video | Phosphorex's Lab Overview Tour (2024 Lab Tour Video Series)

Read more

Complimentary Webinar | Cryo-TEM Analysis of LNPs Across Mixing Systems, including Bleb Structure Formation

Phosphorex & NIS Webinar

Read more

Partnership Opportunities in Drug Delivery (PODD) 2023 Pre-Conference Issue: An Interview with Jarlath Keating, CEO of Phosphorex

Partnership Opportunities in Drug Delivery Editor interviews Jarlath Keating, CEO of Phoshorex . Article entitled "CDMO Innovations to Facilitate New Therapeutics Development"

Read more

Complimentary Webinar | The Right Microfluidic Mixing Platform Plays a Crucial Role in Advancing LNP Clinical Development

Webinar featuring our Formulation Scientist, Sydney Marchando, MS. & Nick Boylan, Ph.D., Director of Nucleic Acid Delivery.

Read more

Article | PPRX-1701, a nanoparticle formulation of 6- bromoindirubin acetoxime, improves delivery and shows efficacy in preclinical GBM models

Glioblastoma (GBM) is a malignant brain tumor that remains among the most formidable cancers.Despite a well-established standard of care of maximal surgical resection followed by radiotherapy plus concomitant temozolomide (TMZ), median survival remains approximately 15 months.

Read more

Development of Long-Acting Injectable Microspheres

Read more

CRS Nanosuspension Formulation Presentation

Our team presents the process of Nanosuspension for the novel Indirubin, for the potential treatment of Glioblastoma.

Read more

PODD: Partnerships in Drug Delivery

Pharma, biotech and the drug delivery industries gather annually at PODD to assess delivery needs, latest trends and information on deals and learn about a wide range of innovative drug delivery technologies that could improve the delivery of various types of drugs. This can include proteins, peptid

Read more

Webinar | Case Study: Development of Nanoparticles for the Systemic Delivery of Antisense Oligonucleotides to the Central Nervous System

Phosphorex's director of nucleic delivery presents on Nanoparticles for the delivery of ASO to the CNS

Read more

Webinar | A Case Study: Nanoparticle Formulation Enables Systemic Delivery of a Therapeutic Agent to Treat Glioblastoma

In collaboration with Brown University, Phosphorex presents on the use the nanoparticle formulation, to enable Systematic Delivery of Tx Agent to treat GBM

Read more